Q1 2025 Fortis Healthcare Ltd Earnings Call Transcript
Key Points
- Fortis Healthcare Ltd (BOM:532843) reported a consolidated top line figure of INR1,859 crores, a growth of 12.2% over Q1 of financial year '24.
- The hospital business revenues grew 14.4% to INR1,549 crores, indicating strong performance in this segment.
- Consolidated operating EBITDA saw an uptick of 25.5%, reaching INR343 crores, yielding a margin of 18.4% versus 16.5% in Q1 of financial year '24.
- Hospital occupancy improved to 67% compared to 64% in Q1 of financial year '24, translating into occupied beds increasing by 4.6%.
- Revenues from digital channels demonstrated robust growth, contributing almost 30% to overall hospital revenues versus 23% in Q1 of financial year '24.
- Operating EBITDA margin in the diagnostics business decreased to 16.1% from 19.4% in Q1 of financial year '24.
- Certain one-off costs in the current quarter, including GST-related liabilities and higher provisions for bad and doubtful debt, impacted the EBITDA margin.
- The diagnostics business is still adjusting to the impact of the Agilus rebranding exercise, which involved extensive rebranding efforts and associated marketing costs.
- The EBITDA margin for some hospitals, such as FEHI and Vashi, has fallen below 10%, indicating underperformance in these facilities.
- The company faces potential financial strain due to the put option valuation of INR1,780 crores for the 31% stake held by private equity investors in Agilus Diagnostics.
Ladies and gentlemen, good day, and welcome to Q1 FY25 post-results conference call of Fortis Healthcare Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Anurag Kalra, Senior Vice President, Investor Relations at Fortis Healthcare Limited. Thank you, and over to you, sir.
Thank you very much. A very good morning and good evening, ladies and gentlemen, and welcome to Fortis Healthcare's quarter one FY25 earnings call.
The call is being chaired by our MD and CEO, Dr. Ashutosh Raghuvanshi. With him, we have our Chief Financial Officer, Mr. Vivek Goyal. From the Agilus side, we have Mr. Anand, the CEO; and Mr. Mangesh Shirodkar, the Chief Financial Officer.
We will start with some opening comments by Dr. Raghuvanshi on the results and the business Performance, followed by which Anand will take you through some of the key highlights of the diagnostics business, and then we can open the floor for question and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |